Format

Send to

Choose Destination
Alzheimers Dement. 2015 Apr;11(4):455-61. doi: 10.1016/j.jalz.2014.01.007. Epub 2014 Apr 21.

Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease.

Author information

1
Tapestry Networks (US Office), Waltham, MA, USA. Electronic address: pbradley@tapestrynetworks.com.
2
School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK.
3
Wolfson Centre for Age Related Diseases, King's College London, London, UK.
4
Brighton & Sussex Medical School, University of Sussex, Brighton, UK.
5
Clinical Neurochemistry Laboratory, Department of Psychiatry & Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
6
European Health Management Association (EHMA), Brussels, Belgium.
7
Federal Institute for Drugs & Medical Devices (BfArM), Bonn, Germany.
8
Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA.
9
Admiral Nursing, Dementia UK, London, UK.
10
Alzheimer Institute (IM2A), Salpêtrière University Hospital, UPMC, Paris, France.
11
Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany.
12
Biogen Idec, Cambridge, MA, USA (formerly Janssen Alzheimer Immunotherapy Research & Development LLC).
13
Italian Medicines Agency (AIFA), Rome, Italy.
14
Alzheimer's Disease and Other Cognitive Disorders Unit, Barcelona Clinical Hospital, Barcelona, Spain; Early Detection Programme, Pasqual Maragall Foundation, Barcelona, Spain.
15
Medicines & Healthcare Products Regulatory Agency (MHRA), London, UK.
16
Sanofi S.A., Paris, France (formerly PET Neurology, GE Healthcare).
17
Primary Care & Ageing, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
18
Independent Consultant in Reimbursement & Pharmacy, Zwolle, Netherlands.
19
Association Internationale de la Mutualité, Brussels, Belgium.
20
Alzheimer's Disease Research Centre, Karolinska Institutet, Stockholm, Sweden.
21
Alzheimer's Disease International (ADI), London, UK.
22
Tapestry Networks (US Office), Waltham, MA, USA. Electronic address: lgoh@tapestrynetworks.com.

Abstract

Health-care stakeholders increasingly recognize that the scientific and economic challenges associated with Alzheimer's disease (AD) are simply too great for individual stakeholder groups to address solely from within their own silos. In the necessary spirit of collaboration, we present in this perspective a set of multicountry multistakeholder recommendations to improve the organization of existing AD and dementia care and the development of new treatments. In brief, the five recommendations are (1) health-care systems must make choices regarding the patient populations to be diagnosed and treated, (2) health-care systems should use an evidence-based standard of care, (3) increased collaboration between public and private institutions is needed to enhance research, (4) reimbursement end points need to be agreed on and validated, and (5) innovative business models should be used to spur the introduction of new medicines.

KEYWORDS:

Alzheimer's disease; Biomarker; Care standard; Clinical development; Collaboration; Diagnosis; Innovation; Multistakeholder; Payer; Reimbursement

PMID:
24751826
DOI:
10.1016/j.jalz.2014.01.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center